CG-001
Prevention of Post-Traumatic Osteoarthritis (PTOA) following ankle fracture
Phase 2Active
Key Facts
Indication
Prevention of Post-Traumatic Osteoarthritis (PTOA) following ankle fracture
Phase
Phase 2
Status
Active
Company
About CartilaGen
CartilaGen is pioneering a first-in-category therapeutic approach to prevent Post-Traumatic Osteoarthritis (PTOA), a debilitating and costly sequela of joint injuries like ankle fractures. Its lead candidate, CG-001, is an intra-articular injection of amobarbital that inhibits mitochondrial Complex I to reduce reactive oxidant species (ROS) and cartilage damage immediately following injury. The company has completed a Phase 1 safety trial, secured Department of Defense funding for a Phase 2 efficacy study, and holds intellectual property protection extending to 2044, targeting a significant unmet need with a seamless surgical workflow integration.
View full company profile